Anika Therapeutics, Inc. Forecast, price target & analysts
Anika Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Anika Therapeutics, Inc. Classifications & Recommendation:
Anika Therapeutics, Inc. Price Target
| Target Price | $16.32 |
| Price | $9.13 |
| Potential |
78.75%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Anika Therapeutics, Inc. 2026 .
The average Anika Therapeutics, Inc. target price is $16.32.
This is
78.75%
register free of charge
$25.20
176.01%
register free of charge
$15.15
65.94%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Anika Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Anika Therapeutics, Inc. stock has an average upside potential 2026 of
78.75%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 119.91 | 113.22 |
| 0.73% | 5.58% | |
| EBITDA Margin | 4.85% | 0.68% |
| 67.65% | 85.97% | |
| Net Margin | -47.03% | -14.81% |
| 31.29% | 68.51% |
5 Analysts have issued a sales forecast Anika Therapeutics, Inc. 2025 . The average Anika Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Anika Therapeutics, Inc. EBITDA forecast 2025. The average Anika Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Anika Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Anika Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.83 | -1.16 |
| 32.09% | 69.71% | |
| P/E | negative | |
| EV/Sales | 0.69 |
5 Analysts have issued a Anika Therapeutics, Inc. forecast for earnings per share. The average Anika Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Anika Therapeutics, Inc....
Current Anika Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barrington Research |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Nov 01 2024 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Oct 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barrington Research:
Locked
➜
Locked
|
Jul 31 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Nov 01 2024 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Oct 22 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
